Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (3,962)	$ (8,333)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of investment	467	5,071
Research and development-acquired license, expensed	1,034	1,011
Stock-based compensation	112
Realized (gain) loss on marketable securities	(424)	44
Unrealized loss on marketable securities	2,049	835
Changes in assets and liabilities:
Prepaid expenses and other assets	16	16
Accounts payable and accrued expenses	(323)	102
Accrued salaries and benefits	5	(244)
Interest receivable on convertible note	(27)
Payable to DatChat		50
Net cash used in operating activities	(1,053)	(1,448)
Cash flows from investing activities
Purchase of marketable securities	(83,586)	(20,378)
Sale of marketable securities	14,335	4,215
Purchase of research and development licenses	(503)	(1,011)
Purchase of convertible note	(2,000)
Net cash used in investing activities	(71,754)	(17,174)
Cash flows from financing activities
Proceeds from issuance common stock and warrants, net of offering cost	77,989	6,549
Proceeds from issuance common stock, net of offering cost		5,095
Proceeds from exercise of warrants	84	7,139
Net cash provided by financing activities	78,073	18,783
Net increase in cash and cash equivalents	5,266	161
Cash and cash equivalents, beginning of period	2,715	91
Cash and cash equivalents, end of period	$ 7,981	252
Non-cash investing and financing activities
Offering cost included in accrued expenses		$ 7